Predictive Health AI
Beyond Monitoring. Toward Earlier Recognition of Risk.
Vital signs reveal what is happening now. Trends and clinical context may help identify changes that deserve attention sooner.
Signal inputs
Context turns measurements into meaning.
CuraVeyra's planned approach combines multiple data sources rather than relying on single thresholds.
AI-assisted risk stratification · concept
Illustrative Demo Data — not a validated clinical prediction.
AI decision support workflow
Seven steps, with clinicians in control.
- 01
Collect approved patient data.
- 02
Verify data completeness and quality.
- 03
Analyze patient trends and selected signal combinations.
- 04
Generate an explainable risk indicator when supported by validated models.
- 05
Present findings to the responsible clinical team.
- 06
Trigger the appropriate care workflow.
- 07
Record outcomes and follow-up actions.
Explainability
Every alert should answer: why now?
Alert explanation · CV-001
Illustrative- Triggering measurement
- Weight 84.6 kg
- Historical trend
- +2.2 kg over 6 days
- Context
- HF protocol · reported breathlessness
- Time of detection
- 08:12
- Severity
- Elevated Risk
- Next workflow step
- Clinician review & patient call
- Acknowledgment
- RN · 08:16
Risk categories
Stable
Within protocol ranges and expected trends.
Attention Needed
A change worth reviewing at the next opportunity.
Elevated Risk
Multiple signals suggest prompt clinical review.
Urgent Clinical Review
Escalation per the organization's protocol.
AI models are under development and validation. Their clinical performance has not yet been established, and demo indicators are not clinical predictions. CuraVeyra supports — never replaces — clinical judgment.
Collaboration context
Connecting Remote Monitoring with Specialized Clinical AI.
Established cardiac AI companies have shown what clinical credibility looks like: explainable outputs, rigorous validation and integration into real care pathways. CuraVeyra's complementary focus is remote monitoring and care coordination.
Validated third-party cardiac AI modules could potentially complement a remote monitoring platform — for example by analyzing ECG events captured at home and routing results into structured clinical workflows. The broader Telemedical project has publicly described collaboration discussions and technological synergy with Powerful Medical.
No integration is completed. Third-party technology is not owned by CuraVeyra, and any third-party regulatory authorization does not extend to CuraVeyra. Any named partnership is subject to confirmation and approval.
Help shape responsible clinical AI.
We're looking for clinical and research partners to support validation planning.